Celares GmbH
Home  |  Contact  |  Imprint
celares GmbH celares GmbH celares GmbH celares GmbH celares GmbH
 
 
 

News release

News release

Merck Millipore and celares GmbH
announce collaboration

New: Discrete 4-arm-PEG Maleimide

New: Discrete 4-arm-PEG Maleimide

The multimerisation with discrete 4-arm PEG facilitates defined linker lenght according to binding requirments

Hydrophilic linkers for ADCs

Hydrophilic linkers for ADCs

celares PEG based linker increase solubility of hydrophobic cytotoxic drugs

Articles & Posters

Highlights in der Produktion rekombinanter Proteine

Highlights in der Produktion rekombinanter Proteine

Bereits zum dritten Mal fand vom 1. bis 3. März 2007 die Halle Conference in Halle an der Saale statt. Rund 400 Vertreter aus dem nationalen und internationalen akademischen und industriellen Bereich präsentierten aktuelle Forschungs- und Entwicklungsergebnisse. Zentrale Themen waren die Entwicklung und Produktion neuer therapeutischer Proteinwirkstoffe und deren Verbesserung durch chemische Modifikation.

BioTOPics 42 BioTOP-Report 2011

BioTOPics 42 BioTOP-Report 2011

You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

Buch Berlin

Buch Berlin

In Buch engagieren sich seit 100 Jahren Mediziner und Forscher gemeinsam für den Wert der Gesundheit. Lernen Sie Buch, seine Partner und die einzigartige Campus- Atmosphäre kennen, in der die Zukunft der Medizin entsteht.

PEGylation of APIT

PEGylation of APIT

APIT (Aplysia punctata ink toxin) is a 60 kDa protein isolated from the defensive ink of the sea hare Aplysia punctata. In the meantime it is produced as a recombinant protein in bacteria. APIT kills tumor cells in an apoptosis independent manner. APIT possesses an L-amino acid oxidase activity that catalyzes the oxidative deamination of L-lysine and Larginine.

PEGylation technology and biopharmaceuticals

PEGylation technology and biopharmaceuticals

Simple modification with polyethylene glycol (PEG) is not only capable of improving the pharmacological properties of a drug, especially for peptide and protein therapeutics, but has also to be considered with regard to its life cycle extension. Dr Frank Leenders of celares GmbH describes PEGylation technologies and how they are impacting biopharmaceutical development.

INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE BY CARRIER-CONJUGATED PEPTIDES

INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE BY CARRIER-CONJUGATED PEPTIDES

How can we improve the efficiency of antigen specific tolerance induction?